A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3-one

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2283-2286

  Mylari, Banavara L ^a,b   Armento, Sandra J ^a   Beebe, David A ^a   Conn, Edward L ^a   Coutcher, James B ^a   Dina, Michael S ^a,c   O'Gorman, Melissa T ^a   Linhares, Michael C ^a   Martin, William H ^a   Oates, Peter J ^a   Tess, David A ^a   Withbroe, Gregory J ^a   Zembrowski, William J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Genentech ^*  (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (5 CHLORO 3 METHYLBENZOFURAN 2 SULFONYL) 2 H PYRIDAZIN 3 ONE; ALDOSE REDUCTASE INHIBITOR; CARBOXYLIC ACID; HYDANTOIN; MINALRESTAT; SORBINIL; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; NONHUMAN; PLASMA HALF LIFE; RAT; SCIATIC NERVE;

ADMINISTRATION, ORAL; ALDEHYDE REDUCTASE; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; FRUCTOSE; HUMANS; HYPOGLYCEMIC AGENTS; LENS, CRYSTALLINE; PERMEABILITY; PYRIDAZINES; RATS; SCIATIC NERVE; SORBITOL; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 12444318652     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034065z     Document Type: Article

References (23)

1. (a) Kinoshita, J. H. A Thirty Year Journey in the Polyol Pathway. Exp. Eye Res. 1990, 50, 567-573.
2. (b) Kinoshita, J. H.; Nishimura, C. The Involvement of Aldose Reductase in Diabetic Complications. Diabetes Metab. Rev. 1988, 4, 323-337.
3. (a) Tilton, R. G.; Chang, K.; Nyengaard, J. R.; Van den Enden, M.; Ido, Y.; Williamson, J. R. Inhibition of Sorbitol Dehydrogenase. Effects on Vascular and Neural Dysfunction in Streptozotocin-Induced Diabetic Rats. Diabetes 1995, 44, 234-242.
4. (b) Williamson, J. R.; Chang, K.; Frangos, M.; Hasan, K. S.; Ido, Y.; Kawamura, T.; Nyengaard, J. R.; Van den Enden, M.; Kilo, C.; Tilton, R. G. Hypergylcemic Pseudohypoxia and Diabetic Complications. Diabetes 1993, 42, 801-813.
5. Cameron, N. E.; Cotter, M. A.; Basso, M.; Hohman, T. C. Comparison of the Effects of Inhibitors of Aldose Reductase and Sorbitol Dehydrogenase on Neurovascular Function, Nerve Conduction and Tissue Polyol Pathway Metabolites in Streptozotocin-Diabetic Rats. Diabetalogia 1997, 40, 271-281.
6. Ao, S.; Shingu, Y.; Kikuchi, C.; Takano, Y.; Nomura, K.; Fujiwara, T.; Ohkubo, Y.; Notsu, Y.; Yamaguchi, I. Characterization of a Novel Aldose Reductase Inhibitor, FR74366, and Its Effects on Diabetic Cataract and Neuropathy in the Rat. Metabolism 1991, 40, 77-87.
7. Eggler, J. F.; Larson, E. R.; Lipinski, C. A.; Mylari, B L.; Urban, F. J. In Advances in Medicinal Chemistry; Maryanoff, E., Maryanoff, C. A., Eds.; Jai Press Inc.: London, England, 1993; Vol. 2, pp 197-246.
8. (a) Malamas, M. S.; Hohman, T. C.; Millen, J. Novel Spirosuecinimide Aldose Reductase Inhibitors Derived from Isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methyl]-6-fluorospiro- [isoquinoline-4(11H),3′-pyrrolidine]-1,2′,3,5′(2H)-tetrone and Congeners. 1. J. Med. Chem. 1994, 37, 2043-2058.
9. (b) Hohman, T. C.; Bochenek, W. J.; Meng, X.; Neefe, L.; Beg, M.; Ari, D. T. Nerve Function and Biochemistry in Diabetic Patients Treated with ARI-509, a Novel Aldose Reductase Inhibitor. Diabetologia 1997, 40, A552.
10. Ho, E. C. M.; Lam, K. S. L.; Chung, S. S. M.; Chung, S. K. Aldose Reductase Deficient Mice Are Alleviated from the Depletion of GSH in the Peripheral Nerve and MNCV Deficit Associated with Diabetes. Diabetes 2001, 50 (Suppl. 2), A59.
11. (a) Demaine, A.; Cross, D.; Millward, A. Polymorphism of the Aldose Reductase Gene and Susceptibility to Retinopathy in Type I Daibetes Mellitus. Invest. Ophthalmol. Visual Sci. 2000, 41, 4064-4068.
12. (b) Heesom, A. E.; Millward, A.; Demaine, A. G. Susceptibility to Diabetic Neuropathy in Patients with Insulin Dependent Diabetes Mellitus Is Associated with a Polymorphism at the 5′ End of the Aldose Reductase Gene. J. Neurol., Neurosurg. Psychiatry 1998, 64, 213-216.
13. Takahayashi, N. J. Pharm. Soc. Jpn. 1956, 76, 1293-1296.
14. Dvornik, D. A Perspective of Aldose Reductase Inhibitors and Diabetic Complications. Croat. Chem. Acta 1996, 69, 613-630.
15. Experimental procedures for phenyl substituted compounds can be found in Patents EP 1236720 and CAN 137:216953.
16. Stribling, D.; Mirrlees, D. J.; Harrison, H. E.; Earl, D. C. Properties of ICI 128,436, a Novel Aldose Reductase Inhibitor, and Its Effects on Diabetic Complications in the Rat. Metabolism 1985, 34 (4), 336-344.
17. (a) Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2- benzothiazolyl]methyl]-1-phthalazineacetic Acid (Zopolrestat) and Congeners. J. Med. Chem. 1991, 34, 108-122.
18. (b) Mylari, B. L.; Beyer, T. A.; Scott, P. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Zembrowski, W. J. Potent, Orally Active Aldose Reductase Inhibitors Related to Zopolrestat: Surrogates for Benzothiazole Side Chain. J. Med. Chem. 1992, 35, 457-465.
19. Wilson, D. K.; Tarle, I.; Petrash, J. M. Quiocho, F. A. Refined 1.8 Å Structure of Human Aldose Reductase Complexed with the Potent Inhibitor Zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.
20. Kato, K.; Nakayama, K.; Mizota, M.; Miwa, I.; Okuda, J. Properties of Novel Aldose Reductase Inhibitors, M16209 and M16287, in Comparison with Known Inhibitors. ONO-2235 and Sorbinil. Chem. Pharm. Bull. (Tokyo) 1991, 39, 540-545.
21. Experimental procedures for heterocyclic substituted pyridazinones can be found in Patents U.S. 2,002,143,017 and CAN 137: 279206.
22. Indole analogue 20 was more conveniently prepared starting from 2-mercaptoindole and following Scheme 1.
23. Robertson, M. J.; Barnes, J. C.; Drew, G. M.; Clark, K. L.; Marshall, F. H.; Michel, A.; Middlemiss, D.; Ross, B. C.; Scopes, D.; Dowle, M. D. Pharmacological Profile of GR117289 in Vitro: A Novel, Potent and Specific Non-Peptide Angiotensin AT1 Receptor Antagonist. Br. J. Pharmacol. 1992, 107, 1173-1180.